HRP20211419T1 - Predviđanje epitopa t-stanica korisnih za cijepljenje - Google Patents
Predviđanje epitopa t-stanica korisnih za cijepljenje Download PDFInfo
- Publication number
- HRP20211419T1 HRP20211419T1 HRP20211419TT HRP20211419T HRP20211419T1 HR P20211419 T1 HRP20211419 T1 HR P20211419T1 HR P20211419T T HRP20211419T T HR P20211419TT HR P20211419 T HRP20211419 T HR P20211419T HR P20211419 T1 HRP20211419 T1 HR P20211419T1
- Authority
- HR
- Croatia
- Prior art keywords
- protein
- modification
- modifications
- modified
- determining
- Prior art date
Links
- 238000002255 vaccination Methods 0.000 title claims 5
- 230000004048 modification Effects 0.000 claims 44
- 238000012986 modification Methods 0.000 claims 44
- 108091005573 modified proteins Proteins 0.000 claims 18
- 102000035118 modified proteins Human genes 0.000 claims 18
- 102000004169 proteins and genes Human genes 0.000 claims 17
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 238000000034 method Methods 0.000 claims 16
- 108091005601 modified peptides Proteins 0.000 claims 11
- 230000035772 mutation Effects 0.000 claims 10
- 239000012634 fragment Substances 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 7
- 102000043131 MHC class II family Human genes 0.000 claims 6
- 108091054438 MHC class II family Proteins 0.000 claims 6
- 230000002163 immunogen Effects 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims 4
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 108700026244 Open Reading Frames Proteins 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010069754 Acquired gene mutation Diseases 0.000 claims 1
- 238000012163 sequencing technique Methods 0.000 claims 1
- 230000037439 somatic mutation Effects 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/30—Detection of binding sites or motifs
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
Claims (12)
1. Postupak za predviđanje jedne ili više imunogenih modifikacija aminokiselina koje su korisne za cijepljenje, naznačen time, što se modifikacije javljaju u proteinu koji sadrži neoantigen povezan sa tumorom pacijenta, gdje postupak obuhvaća korake:
a) utvrđivanja rezultata vezanja modificiranog peptida koji predstavlja fragment modificiranog proteina za jednu ili više molekula MHC klase II kod navedenog pacijenta,
b) utvrđivanja rezultata ekspresije ili zastupljenosti modificiranog proteina, pri čemu utvrđivanje rezultata ekspresije ili zastupljenosti modificiranog proteina obuhvaća utvrđivanje nivoa ekspresije proteina sa kojim je modifikacija povezana i određivanje učestalosti modificiranog proteina u okviru proteina sa kojim je modifikacija povezana, pri čemu se učestalost modificiranog proteina u okviru proteina sa kojim je modifikacija povezana određuje utvrđivanjem učestalosti alelne varijante, i
c) predviđanja jedne ili više imunogenih modifikacija aminokiselina,
gdje rezultat vezanja navedenog peptida za navedenu molekulu MHC klase II odražava vjerojatnost vezanja navedenog peptida za navedenu molekulu MHC klase II,
gdje učestalost alelne varijante predstavlja zbroj detektiranih sekvenci, u konkretnim očitavanjima, koja obuhvaćaju mjesto mutacije i nose mutaciju, podijeljen zbrojem svih detektiranih sekvenci, u konkretnim očitavanjima, koja obuhvaćaju mjesto mutacije,
pri čemu se, za utvrđivanje rezultata ekspresije ili zastupljenosti modificiranog proteina, rezultat nivoa ekspresije proteina sa kojim je modifikacija povezana množi rezultatom učestalosti modificiranog proteina u okviru proteina sa kojim je modifikacija povezana,
gdje se predviđanje imunogenih modifikacija aminokiselina odnosi na predviđanje da li će peptid koji sadrži takve modifikacije aminokiselina biti imunogen, i stoga koristan kao epitop u cijepljenju.
2. Postupak za izbor i/ili rangiranje imunogenih modifikacija aminokiselina koje su korisne za cijepljenje, naznačen time, što se modifikacije javljaju u proteinu koji sadrži neoantigen povezan sa tumorom pacijenta, gdje postupak obuhvaća korake:
a) utvrđivanja rezultata vezanja modificiranog peptida koji je fragment modificiranog proteina za jedan ili više molekula MHC klase II navedenog pacijenta,
i
b) utvrđivanja rezultata ekspresije ili zastupljenosti modificiranog proteina, pri čemu utvrđivanje rezultata ekspresije ili zastupljenosti modificiranog proteina obuhvaća utvrđivanje nivoa ekspresije proteina sa kojim je modifikacija povezana i određivanje učestalosti modificiranog proteina u okviru proteina sa kojim je modifikacija povezana, pri čemu se učestalost modificiranog proteina u okviru proteina sa kojim je modifikacija povezana određuje utvrđivanjem učestalosti alelne varijante,
pri čemu postupak obuhvaća izvođenje koraka a) i b) na dvije ili više različitih modifikacija, i gdje postupak dalje obuhvaća korak:
c) odabira i/ili rangiranja imunogenih modifikacija aminokiselina korisnih za cijepljenje,
gdje rezultat vezanja navedenog peptida za navedenu molekulu MHC klase II odražava vjerojatnost vezanja navedenog peptida za navedenu molekulu MHC klase II,
gdje učestalost alelne varijante predstavlja zbroj detektiranih sekvenci, u konkretnim očitavanjima, koja obuhvaćaju mjesto mutacije i nose mutaciju, podijeljen zbrojem svih detektiranih sekvenci, u konkretnim očitavanjima, koja obuhvaćaju mjesto mutacije,
pri čemu se, za utvrđivanje rezultata ekspresije ili zastupljenosti modificiranog proteina, rezultat nivoa ekspresije proteina sa kojim je modifikacija povezana množi rezultatom učestalosti modificiranog proteina u okviru proteina sa kojim je modifikacija povezana.
3. Postupak prema patentnom zahtjevu 2, koji obuhvaća usporedbu rezultata navedene dvije ili više različitih modifikacija, pri čemu se, poželjno, rezultati navedene dvije ili više različitih modifikacija uspoređuju rangiranjem različitih modifikacija prema njihovim rezultatima vezanja za MHC klase II.
4. Postupak prema bilo kojem od patentnih zahtjeva 1 do 3, koji obuhvaća izvođenje koraka a) na dva ili više različitih modificiranih peptida, pri čemu navedena dva ili više različitih modificiranih peptida sadrže istu modifikaciju/modifikacije.
5. Postupak prema patentnom zahtjevu 4, naznačen time, što
dva ili više različitih modificiranih peptida koji sadrže istu modifikaciju/modifikacije sadrže različite fragmente modificiranog proteina, pri čemu navedeni različiti fragmenti sadrže istu modifikaciju/modifikacije prisutne u proteinu, i/ili
dva ili više različitih modificiranih peptida koji sadrže istu modifikaciju/modifikacije sadrže različite potencijalne fragmente vezanja MHC klase II modificiranog proteina, gdje navedeni fragmenti sadrže istu modifikaciju/modifikacije prisutne u proteinu, i/ili
dva ili više različitih modificiranih peptida koji sadrže istu modifikaciju/modifikacije razlikuju se po dužini i/ili položaju modifikacije/modifikacija.
6. Postupak prema patentnim zahtjevima 4 ili 5, koji dalje obuhvaća odabir modificiranog/ modificiranih peptida od dva ili više različitih modificiranih peptida koji sadrže istu modifikaciju/modifikacije koji imaju vjerojatnost ili imaju najveću vjerojatnost za vezanje za jednu ili više molekula MHC klase II.
7. Postupak prema bilo kojem od patentnih zahtjeva 4 do 6, naznačen time, što se najbolji rezultat vezanja za jednu ili više molekula MHC klase II dva ili više različitih modificiranih peptida koji sadrže istu modifikaciju/modifikacije dodjeljuje modifikaciji/modifikacijama.
8. Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, što se navedeno određivanje nivoa ekspresije proteina sa kojim je modifikacija povezana i/ili određivanje učestalosti modificiranog proteina u okviru proteina sa kojim je modifikacija povezana obavlja na nivou RNK.
9. Postupak prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time, što modificirani peptid sadrži fragment modificiranog proteina, pri čemu navedeni fragment sadrži modifikaciju prisutnu u proteinu.
10. Postupak prema bilo kojem od patentnih zahtjeva 1 do 9, koji dalje obuhvaća identifikaciju nesinonimnih mutacija u jednom ili više područja koji kodiraju proteine.
11. Postupak prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, što se modifikacije aminokiselina identificiraju djelomičnim ili potpunim sekvenciranjem genoma ili transkriptoma jedne ili više stanica, kao što su jedna ili više stanica raka i izborno jedna ili više ne-kancerogenih stanica i identificiranjem mutacija u jednom ili više područja koji kodiraju proteine.
12. Postupak prema patentnom zahtjevu 10 ili 11, naznačen time, što su navedene mutacije somatske mutacije i/ili mutacije raka.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2015/053021 WO2016128060A1 (en) | 2015-02-12 | 2015-02-12 | Predicting t cell epitopes useful for vaccination |
PCT/EP2016/052684 WO2016128376A1 (en) | 2015-02-12 | 2016-02-09 | Predicting t cell epitopes useful for vaccination |
EP16704567.3A EP3256853B1 (en) | 2015-02-12 | 2016-02-09 | Predicting t cell epitopes useful for vaccination |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20211419T1 true HRP20211419T1 (hr) | 2021-12-10 |
Family
ID=52469061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20211419TT HRP20211419T1 (hr) | 2015-02-12 | 2021-09-08 | Predviđanje epitopa t-stanica korisnih za cijepljenje |
Country Status (22)
Country | Link |
---|---|
US (2) | US11156617B2 (hr) |
EP (2) | EP3256853B1 (hr) |
JP (2) | JP6882178B2 (hr) |
KR (3) | KR102359213B1 (hr) |
CN (2) | CN107430132B (hr) |
AU (2) | AU2016217965B2 (hr) |
BR (1) | BR112017017293A2 (hr) |
CA (1) | CA2982971A1 (hr) |
CY (1) | CY1124558T1 (hr) |
DK (1) | DK3256853T3 (hr) |
ES (1) | ES2888430T3 (hr) |
HK (1) | HK1246852A1 (hr) |
HR (1) | HRP20211419T1 (hr) |
HU (1) | HUE056658T2 (hr) |
IL (1) | IL253627B (hr) |
LT (1) | LT3256853T (hr) |
MX (3) | MX2017010332A (hr) |
PL (1) | PL3256853T3 (hr) |
PT (1) | PT3256853T (hr) |
RS (1) | RS62416B1 (hr) |
SI (1) | SI3256853T1 (hr) |
WO (2) | WO2016128060A1 (hr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
LT3134131T (lt) | 2014-04-23 | 2022-02-10 | Modernatx, Inc. | Nukleorūgšties vakcinos |
WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
EP3328394A4 (en) * | 2015-07-30 | 2019-03-13 | ModernaTX, Inc. | PEPTIDE CONCATEMERIC EPITAOPE RNA |
US20170199961A1 (en) | 2015-12-16 | 2017-07-13 | Gritstone Oncology, Inc. | Neoantigen Identification, Manufacture, and Use |
CN108495649A (zh) | 2016-01-08 | 2018-09-04 | 瓦西博迪公司 | 治疗性抗癌新表位疫苗 |
US20170224796A1 (en) | 2016-02-05 | 2017-08-10 | Xeme Biopharma Inc. | Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System |
CN108700566A (zh) | 2016-02-19 | 2018-10-23 | 河谷控股Ip有限责任公司 | 免疫原性调节的方法 |
KR101925040B1 (ko) * | 2016-11-11 | 2018-12-04 | 한국과학기술정보연구원 | Mhc와 펩타이드 사이의 결합 친화성 예측 방법 및 장치 |
RU2022106357A (ru) * | 2017-02-01 | 2022-03-24 | МОДЕРНАТиЭкс, ИНК. | Противораковые рнк-вакцины |
KR102565256B1 (ko) | 2017-02-12 | 2023-08-08 | 바이오엔테크 유에스 인크. | Hla 기반 방법 및 조성물, 및 이들의 용도 |
TWI672503B (zh) * | 2017-03-31 | 2019-09-21 | 行動基因生技股份有限公司 | 致免疫性之癌症特異抗原決定位的排名系統 |
US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
WO2018224166A1 (en) * | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
EP3694532A4 (en) | 2017-10-10 | 2021-07-14 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEOANTIGENS BY MEANS OF HOT SPOTS |
WO2019090343A1 (en) * | 2017-11-06 | 2019-05-09 | Memorial Sloan Kettering Cancer Center | Heat-inactivated vaccinia virus as a vaccine immune adjuvant |
CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
WO2019147921A1 (en) | 2018-01-26 | 2019-08-01 | Nantcell, Inc. | Rapid verification of virus particle production for a personalized vaccine |
EP3743102A1 (en) | 2018-01-26 | 2020-12-02 | Nantcell, Inc. | Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy |
CN108491689B (zh) * | 2018-02-01 | 2019-07-09 | 杭州纽安津生物科技有限公司 | 基于转录组的肿瘤新抗原鉴定方法 |
CA3111903A1 (en) * | 2018-09-27 | 2020-04-02 | Vaccibody As | Method for selecting neoepitopes |
US20210379170A1 (en) * | 2018-11-15 | 2021-12-09 | Nouscom Ag | Selection of cancer mutations for generation of a personalized cancer vaccine |
US20200224206A1 (en) * | 2018-12-05 | 2020-07-16 | Linearx, Inc. | Amplicon Expression Vector Vaccines |
CN113474840A (zh) * | 2018-12-21 | 2021-10-01 | 百欧恩泰美国公司 | 用于预测hla ii类特异性表位及表征cd4+ t细胞的方法和系统 |
CN111621564B (zh) * | 2019-02-28 | 2022-03-25 | 武汉大学 | 一种鉴定有效肿瘤新抗原的方法 |
WO2020221783A1 (en) * | 2019-04-29 | 2020-11-05 | Vaccibody As | Methods for pre-selection of neoepitopes |
KR102184720B1 (ko) * | 2019-10-11 | 2020-11-30 | 한국과학기술원 | 암 세포 표면의 mhc-펩타이드 결합도 예측 방법 및 분석 장치 |
CN111429965B (zh) * | 2020-03-19 | 2023-04-07 | 西安交通大学 | 一种基于多连体特征的t细胞受体对应表位预测方法 |
CN111617238B (zh) * | 2020-06-02 | 2022-12-13 | 苏州药明康德新药开发有限公司 | 小鼠ct26结直肠癌治疗性肿瘤多肽疫苗制剂及其制备方法 |
CN115836350A (zh) | 2020-07-14 | 2023-03-21 | 米尼奥公司 | 用于确定新抗原的呈递可能性的方法、系统和计算机程序产品 |
WO2022110010A1 (zh) * | 2020-11-27 | 2022-06-02 | 苏州吉玛基因股份有限公司 | 免疫激活剂、抗原和抗体在制备预防、治疗肿瘤产品中的应用 |
CN114984198A (zh) * | 2021-02-24 | 2022-09-02 | 中国科学院上海药物研究所 | 包含肿瘤新生抗原纳米制剂和树突状细胞疫苗的试剂盒及其用途 |
CN113012756A (zh) * | 2021-03-08 | 2021-06-22 | 杭州纽安津生物科技有限公司 | 一种个体化肿瘤新生抗原肽的筛选方法及其疫苗制剂 |
CA3227081A1 (en) | 2021-08-24 | 2023-03-02 | Irena RABE | In vitro transcription technologies |
WO2024083345A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Methods and uses associated with liquid compositions |
Family Cites Families (109)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US5804381A (en) | 1996-10-03 | 1998-09-08 | Cornell Research Foundation | Isolated nucleic acid molecule encoding an esophageal cancer associated antigen, the antigen itself, and uses thereof |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
WO1997024447A1 (en) | 1996-01-02 | 1997-07-10 | Chiron Corporation | Immunostimulation mediated by gene-modified dendritic cells |
WO1997041440A1 (en) | 1996-04-26 | 1997-11-06 | Rijksuniversiteit Te Leiden | Methods for selecting and producing t cell peptide epitopes and vaccines incorporating said selected epitopes |
KR100507660B1 (ko) | 1996-09-13 | 2005-08-10 | 리폭센 테크놀로지즈 리미티드 | 리포좀 |
EP0839912A1 (en) | 1996-10-30 | 1998-05-06 | Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) | Infectious clones of RNA viruses and vaccines and diagnostic assays derived thereof |
US6074645A (en) | 1996-11-12 | 2000-06-13 | City Of Hope | Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
AU743066B2 (en) | 1997-11-06 | 2002-01-17 | Roche Diagnostics Gmbh | Tumor-specific antigens, methods for their production and their use for immunization and diagnosis |
US6432925B1 (en) | 1998-04-16 | 2002-08-13 | John Wayne Cancer Institute | RNA cancer vaccine and methods for its use |
EP1117430A1 (en) | 1998-10-05 | 2001-07-25 | Genzyme Corporation | Genes differentially expressed in cancer cells to design cancer vaccines |
KR100922809B1 (ko) | 1999-05-06 | 2009-10-21 | 웨이크 포리스트 유니버시티 | 면역 반응을 유발하는 항원을 동정하기 위한 조성물과 방법 |
EP1261704B1 (en) | 1999-11-30 | 2009-07-01 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
US7462354B2 (en) | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
EP1242108B1 (en) | 1999-12-28 | 2007-07-11 | Pharmexa Inc. | Optimized minigenes and peptides encoded thereby |
CA2398743C (en) * | 2000-01-28 | 2015-06-23 | The Government Of The United States Of America | Novel mhc class ii restricted t cell epitopes from the cancer antigen, ny eso-1 |
EP2248910A1 (en) * | 2000-04-28 | 2010-11-10 | Mannkind Corporation | Epitope synchronization in antigen presenting cells |
EP1292331A2 (en) | 2000-06-07 | 2003-03-19 | Biosynexus Incorporated | Immunostimulatory rna/dna hybrid molecules |
US6472176B2 (en) | 2000-12-14 | 2002-10-29 | Genvec, Inc. | Polynucleotide encoding chimeric protein and related vector, cell, and method of expression thereof |
DE50214801D1 (de) | 2001-06-05 | 2011-01-13 | Curevac Gmbh | Stabilisierte mRNA mit erhöhtem G/C-Gehalt, kodierend für ein virales Antigen |
DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
AUPS054702A0 (en) | 2002-02-14 | 2002-03-07 | Immunaid Pty Ltd | Cancer therapy |
ATE438857T1 (de) | 2002-06-13 | 2009-08-15 | Merck Patent Gmbh | Verfahren für die identifizierung von allo- antigenen und ihren verwendung für krebs therapie und transplantation |
DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
CN101185754A (zh) * | 2002-10-02 | 2008-05-28 | 霍夫曼-拉罗奇有限公司 | 新mhc ii相关肽 |
DE10344799A1 (de) | 2003-09-26 | 2005-04-14 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
JP5645340B2 (ja) | 2003-10-15 | 2014-12-24 | メディゲーネ アクチエンゲゼルシャフトMediGene AG | 活性成分を含有するカチオンリポソームの投与方法 |
PT1692516E (pt) | 2003-10-24 | 2011-03-07 | Immunaid Pty Ltd | Método de terapia |
US7303881B2 (en) | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
DE102004023187A1 (de) | 2004-05-11 | 2005-12-01 | Ganymed Pharmaceuticals Ag | Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie |
DE102004057303A1 (de) | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stabile Kristallmodifikationen von DOTAP Chlorid |
WO2006071990A2 (en) | 2004-12-29 | 2006-07-06 | Mannkind Corporation | Methods to bypass cd+4 cells in the induction of an immune response |
EP1715346A1 (en) * | 2005-04-22 | 2006-10-25 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Method of identifying CD4+ T cell antigens |
BRPI0610235B8 (pt) | 2005-05-09 | 2021-05-25 | Squibb & Sons Llc | anticorpos monoclonais geneticamente modificados e diferentes daqueles encontrados na natureza, ou porção de ligação ao antígeno dos mesmos, usos terapêuticos dos mesmos, composições, imunoconjugado, molécula biespecífica compreendendo os mesmos, molécula de ácido nucléico e vetor de expressão |
UA99701C2 (ru) | 2005-07-01 | 2012-09-25 | Медарекс, Инк. | Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1) |
ES2735531T3 (es) | 2005-08-23 | 2019-12-19 | Univ Pennsylvania | ARN que contiene nucleósidos modificados y métodos de uso del mismo |
DE102005041616B4 (de) | 2005-09-01 | 2011-03-17 | Johannes-Gutenberg-Universität Mainz | Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen |
EP1762575A1 (en) | 2005-09-12 | 2007-03-14 | Ganymed Pharmaceuticals AG | Identification of tumor-associated antigens for diagnosis and therapy |
EP1994181A4 (en) | 2006-02-27 | 2010-05-19 | Univ Arizona | IDENTIFICATION AND USE OF NOVOPEPTIDES FOR THE TREATMENT OF CANCER |
EP2061504A4 (en) | 2006-09-20 | 2010-01-27 | Univ Johns Hopkins | COMBINATION THERAPY FOR CANCER AND INFECTION DISEASES WITH ANTI-B7-H1 ANTIBODIES |
DE102006060824B4 (de) | 2006-12-21 | 2011-06-01 | Johannes-Gutenberg-Universität Mainz | Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten |
NZ578650A (en) | 2006-12-27 | 2011-12-22 | Harvard College | Pd-1 and activated t-cell compositions and methods for the treatment of viral infections and tumors |
US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
US8140270B2 (en) | 2007-03-22 | 2012-03-20 | National Center For Genome Resources | Methods and systems for medical sequencing analysis |
CA2691357C (en) | 2007-06-18 | 2014-09-23 | N.V. Organon | Antibodies to human programmed death receptor pd-1 |
EP2060583A1 (en) | 2007-10-23 | 2009-05-20 | Ganymed Pharmaceuticals AG | Identification of tumor-associated markers for diagnosis and therapy |
SI2276486T1 (sl) | 2008-03-24 | 2014-01-31 | 4Sc Discovery Gmbh | Novi substituirani imidazokinolini |
EP2276495B1 (en) | 2008-04-17 | 2018-11-21 | PDS Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
ES2587963T3 (es) | 2009-07-31 | 2016-10-27 | Ethris Gmbh | ARN con una combinación de nucleótidos no modificados y modificados para la expresión de proteínas |
WO2013040142A2 (en) | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
JP5948319B2 (ja) | 2010-05-14 | 2016-07-06 | ザ ジェネラル ホスピタル コーポレイション | 腫瘍特異的なネオ抗原を同定する組成物および方法 |
BR112013007862A2 (pt) | 2010-10-01 | 2019-09-24 | Moderna Therapeutics Inc | ácidos nucleicos manipulados e métodos de uso dos mesmos. |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
DE102011102734A1 (de) | 2011-05-20 | 2012-11-22 | WMF Württembergische Metallwarenfabrik Aktiengesellschaft | Vorrichtung zum Aufschäumen von Milch, Getränkebereiter mit dieser Vorrichtung und Verfahren zum Aufschäumen von Milch |
NZ742420A (en) * | 2011-05-24 | 2022-10-28 | Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh | Individualized vaccines for cancer |
WO2012159643A1 (en) | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
HUE057725T2 (hu) | 2011-10-03 | 2022-06-28 | Modernatx Inc | Módosított nukleozidok, nukleotidok és nukleinsavak és ezek felhasználása |
PT2791160T (pt) | 2011-12-16 | 2022-07-04 | Modernatx Inc | Composições arnm modificado |
WO2013106496A1 (en) | 2012-01-10 | 2013-07-18 | modeRNA Therapeutics | Methods and compositions for targeting agents into and across the blood-brain barrier |
US9321808B2 (en) | 2012-02-20 | 2016-04-26 | Biontech Ag | Homo- and heterodimeric SMAC mimetic compounds as apoptosis inducers |
US20130255281A1 (en) | 2012-03-29 | 2013-10-03 | General Electric Company | System and method for cooling electrical components |
JP6189415B2 (ja) | 2012-04-02 | 2017-08-30 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 細胞質および細胞骨格タンパク質の産生のための修飾ポリヌクレオチド |
AU2013289939B2 (en) | 2012-07-12 | 2018-08-09 | Persimmune, Inc. | Personalized cancer vaccines and adoptive immune cell therapies |
US20150307542A1 (en) | 2012-10-03 | 2015-10-29 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
KR20230154283A (ko) | 2012-11-01 | 2023-11-07 | 팩터 바이오사이언스 인크. | 세포에서 단백질을 발현시키는 방법들과 생성물들 |
LT2922554T (lt) | 2012-11-26 | 2022-06-27 | Modernatx, Inc. | Terminaliai modifikuota rnr |
EP2964234A4 (en) | 2013-03-09 | 2016-12-07 | Moderna Therapeutics Inc | NON-TRANSLATED HETEROLOGOUS REGIONS FOR MRNA |
EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
WO2014160243A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Purification and purity assessment of rna molecules synthesized with modified nucleosides |
WO2014152211A1 (en) | 2013-03-14 | 2014-09-25 | Moderna Therapeutics, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
EP2971165A4 (en) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS |
WO2014144711A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Analysis of mrna heterogeneity and stability |
WO2014144039A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
EP2971033B8 (en) | 2013-03-15 | 2019-07-10 | ModernaTX, Inc. | Manufacturing methods for production of rna transcripts |
EP2983804A4 (en) | 2013-03-15 | 2017-03-01 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
WO2014152031A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Ribonucleic acid purification |
CA2908434C (en) * | 2013-04-07 | 2021-12-28 | The Broad Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
WO2014180490A1 (en) * | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
WO2015014375A1 (en) | 2013-07-30 | 2015-02-05 | Biontech Ag | Tumor antigens for determining cancer therapy |
JP2016530294A (ja) | 2013-09-03 | 2016-09-29 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | キメラポリヌクレオチド |
EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
WO2015038892A1 (en) | 2013-09-13 | 2015-03-19 | Moderna Therapeutics, Inc. | Polynucleotide compositions containing amino acids |
JP6363179B2 (ja) | 2013-09-26 | 2018-07-25 | バイオンテック アーゲー | Rnaによるシェルを含む粒子 |
WO2015051173A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc | Polynucleotide molecules and uses thereof |
US10385088B2 (en) | 2013-10-02 | 2019-08-20 | Modernatx, Inc. | Polynucleotide molecules and uses thereof |
WO2015058780A1 (en) | 2013-10-25 | 2015-04-30 | Biontech Ag | Method and kit for determining whether a subject shows an immune response |
WO2015085318A2 (en) | 2013-12-06 | 2015-06-11 | Moderna Therapeutics, Inc. | Targeted adaptive vaccines |
EP3053585A1 (en) | 2013-12-13 | 2016-08-10 | Moderna Therapeutics, Inc. | Alternative nucleic acid molecules and uses thereof |
CA2938700A1 (en) | 2014-02-05 | 2015-08-13 | Biontech Ag | A cannula, an injection or infusion device and methods of using the cannula or the injection or infusion device |
LT3134131T (lt) | 2014-04-23 | 2022-02-10 | Modernatx, Inc. | Nukleorūgšties vakcinos |
WO2015172843A1 (en) | 2014-05-16 | 2015-11-19 | Biontech Diagnostics Gmbh | Methods and kits for the diagnosis of cancer |
WO2016062323A1 (en) | 2014-10-20 | 2016-04-28 | Biontech Ag | Methods and compositions for diagnosis and treatment of cancer |
DK4023755T5 (da) | 2014-12-12 | 2024-07-29 | CureVac SE | Kunstige nukleinsyremolekyler til forbedret proteinudtrykkelse |
KR102580696B1 (ko) | 2014-12-30 | 2023-09-19 | 큐어백 에스이 | 신규 인공 핵산 분자 |
WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
WO2016155809A1 (en) | 2015-03-31 | 2016-10-06 | Biontech Rna Pharmaceuticals Gmbh | Lipid particle formulations for delivery of rna and water-soluble therapeutically effective compounds to a target cell |
JP2018524008A (ja) * | 2015-07-14 | 2018-08-30 | パーソナル ジノーム ダイアグノスティクス, インコーポレイテッド | ネオアンチゲン分析 |
US20170199961A1 (en) | 2015-12-16 | 2017-07-13 | Gritstone Oncology, Inc. | Neoantigen Identification, Manufacture, and Use |
CN110636852A (zh) | 2017-04-19 | 2019-12-31 | 磨石肿瘤生物技术公司 | 新抗原的鉴别、制造及使用 |
AU2018279627B2 (en) | 2017-06-09 | 2023-08-10 | Gritstone Bio, Inc. | Neoantigen identification, manufacture, and use |
AU2018328220A1 (en) | 2017-09-05 | 2020-04-23 | Gritstone Bio, Inc. | Neoantigen identification for T-cell therapy |
EP3694532A4 (en) | 2017-10-10 | 2021-07-14 | Gritstone Oncology, Inc. | IDENTIFICATION OF NEOANTIGENS BY MEANS OF HOT SPOTS |
CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
CN111868080A (zh) | 2018-02-27 | 2020-10-30 | 磨石肿瘤生物技术公司 | 利用泛等位基因模型进行的新抗原鉴别 |
-
2015
- 2015-02-12 WO PCT/EP2015/053021 patent/WO2016128060A1/en active Application Filing
-
2016
- 2016-02-09 KR KR1020177025724A patent/KR102359213B1/ko active IP Right Grant
- 2016-02-09 RS RS20211140A patent/RS62416B1/sr unknown
- 2016-02-09 EP EP16704567.3A patent/EP3256853B1/en active Active
- 2016-02-09 WO PCT/EP2016/052684 patent/WO2016128376A1/en active Application Filing
- 2016-02-09 JP JP2017542106A patent/JP6882178B2/ja active Active
- 2016-02-09 HU HUE16704567A patent/HUE056658T2/hu unknown
- 2016-02-09 US US15/550,286 patent/US11156617B2/en active Active
- 2016-02-09 ES ES16704567T patent/ES2888430T3/es active Active
- 2016-02-09 PT PT167045673T patent/PT3256853T/pt unknown
- 2016-02-09 CN CN201680010134.9A patent/CN107430132B/zh active Active
- 2016-02-09 CN CN202110651565.6A patent/CN113484523A/zh active Pending
- 2016-02-09 KR KR1020227003525A patent/KR102670064B1/ko active IP Right Grant
- 2016-02-09 CA CA2982971A patent/CA2982971A1/en active Pending
- 2016-02-09 AU AU2016217965A patent/AU2016217965B2/en active Active
- 2016-02-09 LT LTEPPCT/EP2016/052684T patent/LT3256853T/lt unknown
- 2016-02-09 KR KR1020247017236A patent/KR20240095527A/ko unknown
- 2016-02-09 PL PL16704567T patent/PL3256853T3/pl unknown
- 2016-02-09 DK DK16704567.3T patent/DK3256853T3/da active
- 2016-02-09 BR BR112017017293A patent/BR112017017293A2/pt active Search and Examination
- 2016-02-09 MX MX2017010332A patent/MX2017010332A/es unknown
- 2016-02-09 EP EP21191307.4A patent/EP3954383A1/en active Pending
- 2016-02-09 SI SI201631328T patent/SI3256853T1/sl unknown
-
2017
- 2017-07-24 IL IL253627A patent/IL253627B/en unknown
- 2017-08-10 MX MX2023002858A patent/MX2023002858A/es unknown
- 2017-08-10 MX MX2022000012A patent/MX2022000012A/es unknown
-
2018
- 2018-05-11 HK HK18106129.1A patent/HK1246852A1/zh unknown
-
2021
- 2021-05-06 JP JP2021078678A patent/JP7244571B2/ja active Active
- 2021-09-08 HR HRP20211419TT patent/HRP20211419T1/hr unknown
- 2021-09-14 CY CY20211100811T patent/CY1124558T1/el unknown
- 2021-09-21 US US17/481,243 patent/US20220074948A1/en active Pending
-
2022
- 2022-08-10 AU AU2022215196A patent/AU2022215196A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20211419T1 (hr) | Predviđanje epitopa t-stanica korisnih za cijepljenje | |
HRP20210773T1 (hr) | Predviđanje imunogenosti epitopa t stanica | |
CL2020001894A1 (es) | Editores de nucleobase que comprende proteína de unión a adn programable de ácido nucleico. (divisional solicitud 201902679) | |
HRP20200062T1 (hr) | Postupak proučavanja nukleinskih kiselina | |
BR112021012665A2 (pt) | Polipeptídeos úteis para edição de genes e métodos de uso | |
SG10201906673WA (en) | Artificial nucleic acid molecules | |
Zhou et al. | Mapping cell type-specific transcriptional enhancers using high affinity, lineage-specific Ep300 bioChIP-seq | |
NZ759958A (en) | Neoantigen identification, manufacture, and use | |
JP2021503897A5 (hr) | ||
KR20240023699A (ko) | 바이러스성 암 네오에피토프를 위한 조성물 및 방법 | |
RU2015136780A (ru) | Способы, системы и программное обеспечение для идентификации биомолекул с помощью моделей мультипликативной формы | |
Jing et al. | Tracking the emergence of high affinity aptamers for rhVEGF165 during capillary electrophoresis-systematic evolution of ligands by exponential enrichment using high throughput sequencing | |
EA201990929A1 (ru) | In vitro и клеточные анализы измерения активности ботулинических нейротоксинов | |
CY1114483T1 (el) | Νεα ρυθμιστικα στοιχεια | |
DE602006019475D1 (de) | Verfahren zur mikrorna-identifikation und ihrer anwendungen bei der forschung und menschlichen gesundheit | |
Silva et al. | Selection of novel peptides homing the 4T1 CELL line: exploring alternative targets for triple negative breast cancer | |
JP2011512871A5 (hr) | ||
JP2017517282A5 (hr) | ||
BR112013021056A2 (pt) | anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical | |
US20210061870A1 (en) | Method and system for extracting neoantigens for immunotherapy | |
BR112017012484A2 (pt) | vírus isolado, cultura celular, gene que codifica uma proteína, proteína, fragmento de dna, vírus de vetor recombinante vivo, pseudo-partícula, vacina, anticorpo ou antissoro, método para a preparação de uma vacina, e, kit de teste diagnóstico. | |
JP2022513047A (ja) | 個別化された癌ワクチンの作製のための癌変異の選択 | |
JP2018506295A5 (hr) | ||
HRP20191535T1 (hr) | Individualizirana cjepiva protiv raka | |
SG11201804651XA (en) | Method for determining copy-number variation in sample comprising mixture of nucleic acids |